RNAGene Inc. announced that it has signed a Collaborative Research Agreement with PharmAbcine Inc. Under the agreement, both companies will collaborate to develop next-generation mRNA-based antibody therapeutics by utilizing the proprietary mRNA platform from RNAGENE. Unlike the existing antibody treatments, in which antibodies are artificially produced from external cell lines, mRNA-based therapies involve administration of mRNA in patients so that patients' own cells can produce the encoded therapeutic antibody.